Major Fallout Stocks After Confirmed Ebola Case in United States
With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides of the Ebola story.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 282Reaction to Confirmed Ebola Case in U.S. — UPDATED
News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola have seen their shares pop.
What Else Is Under the Hood for Catalyst Pharma?
ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the study, Firdapse was reported…
Is Ambit Biosciences Getting Enough in Its Buyout?
Ambit Biosciences has announced that it is entering into a merger with Daiichi Sankyo in a deal worth up to $410 million.
Can Repros Therapeutics Shares Still More Than Double?
What do you do when an analyst report comes out that maintains a price target position that implies shares can more than a double ahead?
Will Analysts Start Following Alimera After Its FDA Approval?
Alimera Sciences traded up big on Monday on news that the company received FDA approval for its diabetic macular edema drug Iluvien.
3 Likely Biotech Buyout Candidates
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Coherus Files for IPO: Biotech to Biosimilars
Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering.
Short Sellers Make Moves in Key Biotech Stocks
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
Analyst Now Sees 75% Upside in Sarepta
Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.
DBV Technologies Files for IPO, Sort Of
DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering
Exagen Diagnostics Files for IPO
Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering
A First, Chiropractic IPO Filing: The Joint
The Joint Corporation has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Canaccord Genuity Doubles Price Target for Medivation
Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.